All progressive liberals need to continue accepting medical advice from Liberal politicians and keep rolling up their sleeves for not only safe and effective covid mRNA jabs, but all new mRNA based vaccines. Cancer therapy is the largest sector of public health and the most profitable, and continuing to take oncogenic boosters full of DNA fragments that insert themselves into and disrupt human DNA, and full of SV 40, a known cancer causing agent since the 1950's, will help sustain the cancer therapy industry for generations. Here is a peer reviewed paper:
Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada
tandfonline.com
AbstractFor some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Manufacturing nucleoside-modified mRNA (modRNA) for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of modRNA vaccines, suggesting that the removal of residual DNA template is problematic. Therefore, we quantified the DNA load in a limited number of Pfizer-BioNTech and Moderna COVID-19 modRNA vaccine vials using two independent methods. Total DNA and specific DNA targets were quantified by Qubit fluorometry and quantitative polymerase chain reaction (qPCR), respectively on 32 vials representing 16 unique vaccine lots. RNase A treatment was used to assess the impact of RNA crosstalk in DNA fluorometry. A preliminary assessment of DNA fragment length and DNase I sensitivity were also performed. Total DNA ranged 371–1,548?ng/dose and 1,130–6,280?ng/dose in Pfizer and Moderna products, respectively. Specific DNA of multiple plasmid DNA targets ranged 0.22–7.28?ng/dose for Pfizer, and 0.01–0.78?ng/dose for Moderna. The SV40 promoter-enhancer-ori(0.25–23.72?ng/dose) was only detected in Pfizer vials. Oxford Nanopore sequencing of one vial found mean and maximum DNA fragment lengths of 214?bp and 3.5?kb, respectively. These data demonstrate the presence of 1.23?×?108to 1.60?×?1011 plasmid DNA fragments per dose encapsulated in lipid nanoparticles. Using fluorometry, total DNA in all vials tested exceeded the regulatory limit for residual DNA set by the US Food & Drug Administration (FDA) and the World Health Organization (WHO) by 36–153-fold for Pfizer and 112–627-fold for Moderna after accounting for nonspecific binding to modRNA. When tested by qPCR, all Moderna vials were within the regulatory limit, but 2/6 Pfizer lots (3 vials) exceeded the regulatory limit for the SV40 promoter-enhancer-ori by 2-fold. The presence of the SV40 promoter-enhancer element in Pfizer vials raises significant safety concerns. This study emphasizes the importance of methodological considerations when quantifying residual plasmid DNA in modRNA products, considering increased LNP transfection efficiency, and cumulative dosing presents significant and unquantified risks to human health.
Conclusion
These data demonstrate the presence of billions to hundreds of billions of DNA molecules per dose in the modRNA COVID-19 products tested. Using fluorometry coupled with RNase A digestion, all products tested exceeded the guidelines for residual DNA set by the FDA and WHO of 10?ng/dose by 36–627-fold. qPCR testing showed that all Moderna vials were within the regulatory limit and that 3 Pfizer vials exceeded the regulatory limit for the SV40 promoter-enhancer-ori and showed much greater intra- and inter-lot variability. qPCR underestimates the total DNA with results varying greatly by genomic target emphasizing the importance of using more than one assay to accurately determine the DNA load. It is important that regulators produce clear and consistent guidelines on how to quantify mRNA and plasmid DNA in modRNA vaccines. The PCR results for the most recent XBB.1.5 Moderna and Pfizer vaccines suggest that DNA residues have not been reduced from previous vaccine versions.
Our findings extend existing concerns about vaccine safety and call into question the relevance of guidelines conceived before the introduction of efficient transfection using LNPs. With several obvious limitations, we urge that our work is replicated under forensic conditions and that guidelines be revised to account for highly efficient DNA transfection and cumulative dosing.
This work highlights the need for regulators and industry to adhere to the precautionary principle and provide sufficient and transparent evidence that products are safe and effective, and disclose the details of their composition and method of manufacture. |
